8EF4 | pdb_00008ef4

Solution structural bundle of bivalirudin - a bivalent hirudin based thrombin inhibitor


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report

Validation slider image for 8EF4

This is version 1.2 of the entry. See complete history

Literature

Comprehensive solution NMR characterization of bivalirudin, a direct thrombin inhibitor peptide, and its process impurities by heteronuclear spectral fingerprinting at natural isotopic abundance.

Mishra, S.H.Kaur, A.Vu, D.Bhavaraju, S.

(2026) J Pharm Biomed Anal 281: 117684-117684

  • DOI: https://doi.org/10.1016/j.jpba.2026.117684
  • Primary Citation Related Structures: 
    8EF4

  • PubMed Abstract: 

    Bivalirudin is a 20-residue synthetic peptide that functions as a bivalent thrombin inhibitor by simultaneously engaging thrombin's active site and exosite I. Despite its widespread clinical use, comprehensive NMR-based characterization of bivalirudin and its process-related impurities has not been reported. Here, we present the first complete heteronuclear NMR analysis of bivalirudin and two major impurities-[Asp9]-bivalirudin (a deamidation-related impurity standard) and [desGlu13]-bivalirudin (a synthesis deletion)-at natural isotopic abundance. Using a combination of 1D and 2D 1 H, 13 C, and 15 N NMR experiments in DMSO-d₆ and aqueous solution, we achieved near-complete backbone and side-chain assignments, now deposited in the BMRB. We demonstrate that 2D heteronuclear amide maps can unambiguously differentiate the parent peptide from its process impurities. Additionally, we report the first solution-state NMR structure of free bivalirudin, revealing a compact architecture wherein the active site- and exosite-binding segments are spatially proximate, potentially reflecting a pre-binding intermediate. This study establishes a practical spectral reference framework and simplified 2D heteronuclear spectral fingerprints for structural integrity assessment and impurity tracking of bivalirudin.


  • Organizational Affiliation
    • National Institute of Standards and Technology, (formerly at US Pharmacopeial Convention, Rockville, MD, USA), Gaithersburg, MD, USA; Institute for Biosciences and Biotechnology Research, University of Maryland, College Park, Rockville, MD, USA. Electronic address: shmishra@umd.edu.

Macromolecule Content 

  • Total Structure Weight: 2.18 kDa 
  • Atom Count: 155 
  • Modeled Residue Count: 20 
  • Deposited Residue Count: 20 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Bivalirudin20Hirudo medicinalisMutation(s): 0 
UniProt
Find proteins for P09945 (Hirudo medicinalis)
Explore P09945 
Go to UniProtKB:  P09945
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP09945
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2022-10-05
    Type: Initial release
  • Version 1.1: 2024-11-13
    Changes: Data collection, Database references, Structure summary
  • Version 1.2: 2026-08-12
    Changes: Database references